Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression (Q43255238)
Jump to navigation
Jump to search
scientific article published on 24 October 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression |
scientific article published on 24 October 2009 |
Statements
1 reference
Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression (English)
1 reference
Carlo Aul
1 reference
Aristoteles Giagounidis
1 reference
Gudrun Göhring
1 reference
Guntram Büsche
1 reference
Hans Heinrich Kreipe
1 reference
Martin Zimmermann
1 reference
Eva Hellström-Lindberg
1 reference
Brigitte Schlegelberger
1 reference
24 October 2009
1 reference
1 reference
89
1 reference
4
1 reference
365-374
1 reference
Identifiers
1 reference
1 reference